THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease.
OphthalmologyJun 1, 2026 (epub)
Clinical ResearchOphthalmology
Michael T Yen, Kimberly Cockerham, Peerooz Saeed et al.
✦ AI-curated · Sources linked
In 30 seconds
The THRIVE study evaluated the efficacy and safety of veligrotug, a monoclonal antibody, in adults with moderate-to-severe active thyroid eye disease (TED) in a phase 3 randomized controlled trial. Results showed significant improvements at week 15, with a proptosis responder rate of 70% for veligrotug compared to 5% for placebo (P < 0.001).
Key findings
- Proptosis responder rate at week 15 was 70% for veligrotug versus 5% for placebo.
- Overall responder rate was 67% for veligrotug compared to 5% for placebo.
- Mean proptosis reduction was 2.90 mm for veligrotug versus 0.48 mm for placebo.
- Diplopia improvement occurred in 59% of patients receiving veligrotug versus 20% for placebo.
Why it matters
This study highlights a potential new treatment for active thyroid eye disease, addressing significant unmet needs in this patient population. The rapid and sustained improvements in symptoms could enhance patient quality of life.